# US 2012/0252037 A1 · Stimulatory auto-antibodies to the pdgf receptor as pathology marker and therapeutic target

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252037 A1
- Document ID: US20120252037A1
- Status: Published application
- Kind: A1
- Application number: 13/247,127
- Filed: 2011-09-28
- Published: 2012-10-04
- Earliest claimed: 2005-07-28
- Inventors: Vittorio Enrico AVVEDIMENTO; Armando GABRIELLI; Mariarosa SANTILLO; Ada FUNARO; Michele LUCHETTI; Silvia SVEGLIATI BARONI
- Web page: https://patentgrep.com/patent/US20120252037A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- A61K 38/179: {for growth factors; for growth regulators}
- A61P 17/00: Drugs for dermatological disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/6854: {Immunoglobulins}
- G01N 2800/245: Transplantation related diseases, e.g. graft versus host disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An in vitro method for detecting the presence in a body sample of auto-antibodies for the PDGF receptor suitable for the diagnosis and prognosis of autoimmune diseases, in particular the systemic sclerosis and related diagnostic kits. Use of an inhibitor of ROS and/or Ras-ERK1/2 for the preparation of a medicament for therapeutic treatment of autoimmune diseases or of treating the Graft-Versus-Host-Reaction (GVHR). Pharmaceutical composition comprising an effective amount of an inhibitor of ROS and/or Ras-ERK1/2, and proper diluents, and/or excipients, and/or adjuvants.

## Claims

### Claim 1

An in vitro method for detecting the presence in a body sample of an auto-antibody for a PDGF receptor comprising:
a) incubating the body sample with an effective amount of a specific ligand for the auto-antibody for the PDGF receptor in conditions allowing the binding and the formation of a ligand auto-antibody complex; and
b) detecting a bound auto-antibody, or the ligand auto-antibody complex, if present.

### Claim 2 (depends on 1)

The method of claim 1 wherein the specific ligand is a PDGF receptor or an immunoreactive fragment or derivative thereof.

### Claim 3 (depends on 2)

The method of claim 2 wherein said immunoreactive fragment is comprised in the extracellular region of PDGFRA and/or PDGFRB.

### Claim 4 (depends on 3)

The method of claim 3 wherein said immunoreactive fragment comprised in the extracellular region of PDGFRA and/or PDGFRB is comprised in the first 550 amino acids from the NH terminus of the amino acid sequence of the human PDGFRA NP008197, (SEQ ID No. 7) and/or PDGFRB NP0026000 (SEQ ID No. 8).

### Claim 5 (depends on 1)

The method of claim 1 further comprising diagnosing and prognosing an autoimmune disease.

### Claim 6 (depends on 5)

The method of claim 5 wherein the autoimmune disease is systemic sclerosis.

### Claim 7 (depends on 5)

The method of claim 5 further comprising discriminating between Raynaud phenomenon and systemic sclerosis.

### Claim 8 (depends on 1)

The method of claim 1 further comprising diagnosing a Graft-Versus-Host-Reaction (GVHR).
